Patents Assigned to Edge Therapeutics, Inc.
  • Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
    Patent number: 10092524
    Abstract: The described invention provides a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury using a flowable sustained release particulate composition.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: October 9, 2018
    Assignee: EDGE THERAPEUTICS, INC.
    Inventor: R. Loch Macdonald
  • Polymorph compositions, methods of making, and uses thereof
    Patent number: 9399019
    Abstract: The described invention provides a biodegradable, biocompatible delivery system of flowable sustained release microparticulate composition of a substantially pure crystalline form of a bioactive agent such as, for example, nimodipine, a process of preparing a therapeutic form of a substantially pure crystalline form of the bioactive agent and a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: July 26, 2016
    Assignees: Evonik Corporation, Edge Therapeutics, Inc.
    Inventors: R. Loch Macdonald, Cara R. Davis, Kevin Burton, Gary Winchester, Angela R. Stella, Parissa Heshmati
  • Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
    Patent number: 9364432
    Abstract: The described invention provides a flowable sustained release microparticulate composition, a kit for treating at least one cerebral artery in a subarachnoid space at risk of interruption due to a brain injury, a method of preparing the composition, and a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: June 14, 2016
    Assignee: Edge Therapeutics, Inc.
    Inventors: R. Loch Macdonald, Brian A. Leuthner
  • Polymorph Compositions, Methods of Making, and Uses Thereof
    Publication number: 20140271895
    Abstract: The described invention provides a biodegradable, biocompatible delivery system of flowable sustained release microparticulate composition of a substantially pure crystalline form of a bioactive agent such as, for example, nimodipine, a process of preparing a therapeutic form of a substantially pure crystalline form of the bioactive agent and a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury.
    Type: Application
    Filed: July 16, 2013
    Publication date: September 18, 2014
    Applicants: EDGE THERAPEUTICS, INC., Evonik Corporation
    Inventors: R. Loch Macdonald, Cara R. Davis, Kevin Burton, Gary Winchester, Angela R. Stella
  • DRUG DELIVERY SYSTEM FOR THE PREVENTION OF CEREBRAL VASOSPASM
    Publication number: 20130022660
    Abstract: The present invention relates to the treatment and prevention of vasospasm. The present invention provides a system for treating a cerebral vasospasm in a human utilizing a pharmaceutical composition and administrating a therapeutically effective amount of the pharmaceutical composition to a predetermined location in close proximity to a cerebral artery within a subarachnoid space wherein the pharmaceutical composition produces a localized pharmacologic effect thereby treating the cerebral vasospasm.
    Type: Application
    Filed: July 22, 2012
    Publication date: January 24, 2013
    Applicant: EDGE THERAPEUTICS, INC.
    Inventors: R. Loch Macdonald, Brian A. Leuthner
  • Drug delivery system for the prevention of cerebral vasospasm
    Patent number: 8303974
    Abstract: The present invention relates to the treatment and prevention of vasospasm. The present invention provides a system for treating a cerebral vasospasm in a human utilizing a pharmaceutical composition and administrating a therapeutically effective amount of the pharmaceutical composition to a predetermined location in close proximity to a cerebral artery within a subarachnoid space wherein the pharmaceutical composition produces a localized pharmacologic effect thereby treating the cerebral vasospasm.
    Type: Grant
    Filed: June 11, 2008
    Date of Patent: November 6, 2012
    Assignee: Edge Therapeutics, Inc.
    Inventors: R. Loch Macdonald, Brian Leuthner
  • Methods and compositions to treat hemorrhagic conditions of the brain
    Patent number: 8252302
    Abstract: The described invention provides a nonhuman animal model system for hemorrhagic brain conditions, methods for evaluating a substance for treating the hemorrhagic brain condition in a mammal, methods for treating hematoma expansion or recurrent rebleeding resulting from hemorrhagic brain conditions in a mammal, and pharmaceutical compositions for administration into or at a distance proximal to the hemorrhagic brain condition.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: August 28, 2012
    Assignee: Edge Therapeutics, Inc.
    Inventor: R. Loch Macdonald